ClinicalTrials.gg
TerminatedNCT04927702Updated Feb 27, 2026Results posted

Assessment of Wound Closure Comparing Synthetic Hybrid-Scale Fiber Matrix With Standard of Care in Treating Diabetic Foot Ulcers (DFU) and With Living Cellular Skin Substitute in Treating Venous Leg Ulcers (VLU)

An interventional study of Synthetic Hybrid-Scale Fiber Matrix and Standard of Care in Diabetic Foot Ulcer and Venous Leg Ulcer, sponsored by Acera Surgical, Inc.. Terminated at 6 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-27.

Sponsored by Acera Surgical, Inc. (part of Solventum) · Not applicable, Interventional, and Treatment

How we know

Why this study was terminated
Study was terminated due to slow enrollment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Diabetic Foot by Solventum — none open to participants now, none under way, none of them phase 3. Diabetic Foot · Solventum.

Started
2021
with 1 other
No phase
8 of 12
none open now
Registered
12th of 12
by date

Among the 12 studies in Diabetic Foot by Solventum, this one is one of 2 that started in 2021, is one of 8 with no phase, and was the 12th registered.

Diabetic Foot

1,079 studies on the registry are indexed under Diabetic Foot; 221 are open to participants now.

Browse Diabetic Foot studies →

Open to participants now

None of the 12 studies in Diabetic Foot by Solventum is open now. The open studies under Diabetic Foot, anywhere →

Who these studies take

Of the 139 Diabetic Foot studies recruiting now, 98 (71%) set no upper age limit and 12 (9%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies in Diabetic Foot by Solventum as a file.
02

Study summary

In participants with diabetic foot ulcers (DFUs), this study will assess complete wound closure by comparing synthetic hybrid-scale fiber matrix (Restrata®) with standard of care.

In participants with venous leg ulcers (VLUs), this study will assess complete wound closure by comparing synthetic hybrid-scale fiber matrix (Restrata®) with living cellular skin substitute (Apligraf®)

03

Conditions studied

  • Diabetic Foot Ulcer
  • Venous Leg Ulcer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria for Participants with Diabetic Foot Ulcers:

  1. Participant is at least 18 years old
  2. Participant is willing and capable of complying with all protocol requirements
  3. Participant or legally authorized representative (LAR) is willing to provide written
  4. Participant has Type 1 or Type 2 diabetes (criteria for the diagnosis of diabetes mellitus per American Diabetes Association)
  5. Ulcer(s) must be located at least in part on the foot or ankle
  6. Ulcer(s) must be present for more than 28 days prior to randomization and initial application of study product, and has not adequately responded to conventional ulcer therapy
  7. Wound size must be >1.0 cm\^2 and \< 25 cm\^2 on the day of randomization and initial application of the study product, after initial debridement
  8. Participant has adequate circulation to the affected extremity(ies), as demonstrated by at least ONE of the following within 60 days prior to enrollment/randomization:

    1. Dorsum transcutaneous oxygen test (TcPO2) of study leg(s) with results ≥40mmHg, OR
    2. Ankle-Brachial Index (ABI) of study leg(s) with results of ≥ 0.7 and ≤ 1.3, OR
    3. Toe-Brachial Index (TBI) of study extremity(ies) with results of ≥ 0.5

Exclusion Criteria for Participants with Diabetic Foot Ulcers:

  1. Participant has been previously enrolled into this study, or is currently participating in another prospective drug or device study that has not reached its primary endpoint
  2. Participant is pregnant, breast feeding or planning to become pregnant
  3. Participant has a known allergy to resorbable suture materials, e.g. Polyglactin 910 (PGLA), Polydioxanone (PDS)
  4. Participant has a less than six months as assessed by the investigator
  5. Participant has received skin substitutes during the screening period or within 14 days prior to beginning of screening period
  6. Participant has an additional wound within 3 cm of the study wound(s) or study wounds are less than 3 cm apart
  7. A1c > 12 percent within 3 months prior to randomization
  8. Participant not in reasonable metabolic control in the judgment of the investigator
  9. Participant with a known history of poor compliance with medical treatments
  10. Participant currently undergoing cancer treatment
  11. Participant has been diagnosed with at least one of the following connective tissue diseases: lupus, vasculitis, sickle cell, or uncontrolled rheumatoid arthritis
  12. Participant is taking parenteral or any cytotoxic agents for 7 consecutive days during the screening period or up to 30 days before the screening period. Chronic oral steroid use is not excluded if dose is \< 10 mg per day for prednisone.
  13. Active infection, undrained abscess, or critical colonization of the wound(s) with bacteria in the judgment of the investigator
  14. Osteomyelitis or exposed bone, probes to bone or joint capsule on investigator's exam or radiographic evidence
  15. Participant unwilling or unable to safely utilize appropriate offloading device to unweight wound(s)
  16. Study ulcer(s) experiences greater than 30 percent reduction over the 2-week screening period
  17. Participant also has a venous leg ulcer that is enrolled into this study

Inclusion Criteria for Participants with Venous Leg Ulcers:

  1. Participant is at least 18 years old
  2. Participant is willing and capable of complying with all protocol requirements
  3. Participant or legally authorized representative (LAR) is willing to provide written informed consent
  4. Participant has peripheral venous disease per investigator judgment or diagnostic confirmation
  5. Ulcer(s) must be venous in origin, located on a lower extremity
  6. Ulcer(s) must be present for more than 28 days prior to randomization and initial application of study product, and has not adequately responded to conventional ulcer therapy
  7. Wound(s) size must be >1.0 cm\^2 and \< 50 cm\^2 on the day of randomization and initial application of the study product, after initial debridement
  8. Participant has adequate circulation to the affected extremity(ies), as demonstrated by at least ONE of the following within 60 days prior to enrollment/randomization:

    1. Dorsum transcutaneous oxygen test (TcPO2) of study leg(s) with results ≥ 40mmHg, OR
    2. Ankle-brachial index (ABI) of study leg(s) with results of ≥ 0.7 and ≤ 1.52, OR
    3. Toe-Brachial Index (TBI) of study leg(s) with results of ≥ 0.5, OR
    4. Doppler arterial waveforms, which are triphasic or biphasic at the ankle of the affected leg(s)

Exclusion Criteria for Participants with Venous Leg Ulcers:

  1. Participant has been previously enrolled into this study, or is currently participating in another prospective drug or device study that has not reached its primary endpoint
  2. Participant is pregnant, breast feeding or planning to become pregnant
  3. Participant has a known allergy to resorbable suture materials, e.g. Polyglactin 910 (PGLA), Polydioxanone (PDS)
  4. Participant has a known allergy to bovine materials or agarose shipping materials
  5. Participant has a life expectancy less than six months as assessed by the investigator
  6. Participant has received skin substitutes during the screening period or within 14 days prior to the beginning of the screening period
  7. Participant has an additional wound within 3 cm of the study wound or study wounds are less than 3 cm apart
  8. Hgb A1c > 12 percent within 3 months prior to randomization in patients with a known history of diabetes
  9. Participant is not in reasonable metabolic control in the judgment of the investigator
  10. Participant has a known history of poor compliance with medical treatments
  11. Participant currently undergoing cancer treatment
  12. Participant has been diagnosed with at least one of the following autoimmune connective tissue diseases: lupus, vasculitis, sickle cell, or uncontrolled rheumatoid arthritis
  13. Participant is taking parenteral corticosteroids or any cytotoxic agents for 7 consecutive days during the screening period or up to 30 days before the screening period. Chronic oral steroid use is not excluded if dose is \< 10 mg per day for prednisone.
  14. Active infection, undrained abscess, or critical colonization of the wound(s) with bacteria in the judgment of the investigator
  15. Participant unwilling or unable to tolerate use of compression therapy for the duration of the study
  16. Study ulcer(s) experiences greater than 30 percent reduction over the 2-week run-in period
  17. Participant also has a diabetic foot ulcer that is enrolled into this study
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    Diabetic Foot Ulcer Participants Assigned to Synthetic Hybrid-Scale Fiber Matrix (Restrata®)

    Biweekly (every 2 weeks) application for either 12 weeks or until 100 percent epithelialization / wound closure (whichever occurs first)

    Device: Synthetic Hybrid-Scale Fiber Matrix

  • Active comparator
    Diabetic Foot Ulcer Participants Assigned to Standard of Care

    Weekly application for either 12 weeks or until 100 percent epithelialization / wound closure (whichever occurs first)

    Device: Standard of Care

  • Experimental
    Venous Leg Ulcer Participants Assigned to Synthetic Hybrid-Scale Fiber Matrix (Restrata®)

    Biweekly (every 2 weeks) application for either 16 weeks or until 100 percent epithelialization / wound closure (whichever occurs first)

    Device: Synthetic Hybrid-Scale Fiber Matrix

  • Active comparator
    Venous Leg Ulcer Participants Assigned to Living Cellular Skin Substitute (Apligraf®)

    Biweekly (every 2 weeks) application for either 16 weeks or until 100 percent epithelialization / wound closure (whichever occurs first)

    Device: Living Cellular Skin Substitute

Interventions

  • DeviceSynthetic Hybrid-Scale Fiber Matrix

    A synthetic absorbable skin substitute indicated for use in the local management of wounds. It is made of small synthetic fibers that are designed to be similar to the structure of human skin.

    Also known as: Restrata

  • DeviceStandard of Care

    To ensure off-loading, each patient will be fitted with an off-loading device based on the investigator's decision, e.g. a boot for forefoot and a heel protector for hindfoot. Patients is instructed on how to care for the surgical site, utilize an off-loading device, and keep the surgical site moist and clean. If the wound is dry, a hydrogel category dressing type should be used. If the wound has exudate, an alginate or foam dressing is recommended.

  • DeviceLiving Cellular Skin Substitute

    An absorbable skin substitute comprised of human and bovine (cow) tissues indicated for use in the local management of wounds.

    Also known as: Apligraf

06

What researchers measure

Primary outcomes

  1. For Diabetic Foot Ulcers, Number of Wounds With 100 Percent Epithelialization (Closure) of Wound

    The number of wounds in each treatment arm that achieved 100 percent epithelialization of wound as assessed by a blinded evaluator via review of a three-dimensional high resolution photo of the wound plus confirmation of no drainage or need for additional dressing 2 weeks after 100 percent epithelialization

    Time frame: 12 weeks

  2. For Venous Leg Ulcers, Number of Wounds With 100 Percent Epithelialization (Closure) of Wound

    The number of wounds in each treatment arm with 100 percent epithelialization of wound as assessed by a blinded evaluator via review of a three-dimensional high resolution photo of the wound plus confirmation of no drainage or need for additional dressing 2 weeks after 100 percent epithelialization

    Time frame: 16 weeks

Secondary outcomes

  1. Percentage Change in Wound Area

    Wound area measurements will be made via a three-dimensional high resolution photo of the wound with automated measurements. Mean percent wound change will be calculated for each treatment arm/group with Week 1 as the baseline value. Change is calculated using the 2-week follow up visit after wound closure for wounds that achieved closure, or for wounds that did not achieve closure, the Week 12 wound area for DFUs and Week 16 wound area for VLUs.

    Time frame: Weekly assessments for 12 weeks for DFU participants (16 weeks for VLU participants), or until 100 percent epithelialization, whichever occurs first.

  2. Time to 100 Percent Epithelialization

    The number of weeks from initial application of study product until 100 percent epithelialization is first identified.

    Time frame: 12 weeks for DFU wounds (16 weeks for VLU wounds), or until 100 percent epithelialization, whichever occurs first.

  3. Total Number of Product Applications

    The number of study applications including the initial application until 12 weeks for DFU patients and 16 weeks for VLU patients, or until 100% re-epithelialization, whichever occurs first

    Time frame: Initial application until 12 weeks for DFU patients and 16 weeks for VLU patients, or until 100% re-epithelialization, whichever occurs first

07

Results

Posted Feb 27, 2026
Limitations and caveats
Early termination leading to small numbers of subjects analyzed

Participant flow

Participant flow — Overall Study
MilestoneDiabetic Foot Ulcer Participants Assigned to Synthetic Hybrid-Scale Fiber Matrix (Restrata®)Diabetic Foot Ulcer Participants Assigned to Standard of CareVenous Leg Ulcer Participants Assigned to Synthetic Hybrid-Scale Fiber Matrix (Restrata®)Venous Leg Ulcer Participants Assigned to Living Cellular Skin Substitute (Apligraf®)
Started8101416
Completed261113
Not completed6433
Withdrew: Study closure5432
Withdrew: Lost to follow-up1001

Outcome measures

PrimaryFor Diabetic Foot Ulcers, Number of Wounds With 100 Percent Epithelialization (Closure) of Wound

The number of wounds in each treatment arm that achieved 100 percent epithelialization of wound as assessed by a blinded evaluator via review of a three-dimensional high resolution photo of the wound plus confirmation of no drainage or need for additional dressing 2 weeks after 100 percent epithelialization

Time frame:
12 weeks
Reported as:
Count of units · wounds
For Diabetic Foot Ulcers, Number of Wounds With 100 Percent Epithelialization (Closure) of Wound
woundsDiabetic Foot Ulcer Participants Assigned to Synthetic Hybrid-Scale Fiber Matrix (Restrata®)Diabetic Foot Ulcer Participants Assigned to Standard of Care
For Diabetic Foot Ulcers, Number of Wounds With 100 Percent Epithelialization (Closure) of Wound21
PrimaryFor Venous Leg Ulcers, Number of Wounds With 100 Percent Epithelialization (Closure) of Wound

The number of wounds in each treatment arm with 100 percent epithelialization of wound as assessed by a blinded evaluator via review of a three-dimensional high resolution photo of the wound plus confirmation of no drainage or need for additional dressing 2 weeks after 100 percent epithelialization

Time frame:
16 weeks
Reported as:
Count of units · wounds
For Venous Leg Ulcers, Number of Wounds With 100 Percent Epithelialization (Closure) of Wound
woundsVenous Leg Ulcer Participants Assigned to Synthetic Hybrid-Scale Fiber Matrix (Restrata®)Venous Leg Ulcer Participants Assigned to Living Cellular Skin Substitute (Apligraf®)
For Venous Leg Ulcers, Number of Wounds With 100 Percent Epithelialization (Closure) of Wound14
SecondaryPercentage Change in Wound Area

Wound area measurements will be made via a three-dimensional high resolution photo of the wound with automated measurements. Mean percent wound change will be calculated for each treatment arm/group with Week 1 as the baseline value. Change is calculated using the 2-week follow up visit after wound closure for wounds that achieved closure, or for wounds that did not achieve closure, the Week 12 wound area for DFUs and Week 16 wound area for VLUs.

Time frame:
Weekly assessments for 12 weeks for DFU participants (16 weeks for VLU participants), or until 100 percent epithelialization, whichever occurs first.
Reported as:
Mean · Percentage change
Percentage Change in Wound Area
Percentage changeDiabetic Foot Ulcer Participants Assigned to Synthetic Hybrid-Scale Fiber Matrix (Restrata®)Diabetic Foot Ulcer Participants Assigned to Standard of CareVenous Leg Ulcer Participants Assigned to Synthetic Hybrid-Scale Fiber Matrix (Restrata®)Venous Leg Ulcer Participants Assigned to Living Cellular Skin Substitute (Apligraf®)
Percentage Change in Wound Area-100 ± 0-64.9 ± 53.2-14.2 ± 77.4-52.7 ± 48.8
SecondaryTime to 100 Percent Epithelialization

The number of weeks from initial application of study product until 100 percent epithelialization is first identified.

Time frame:
12 weeks for DFU wounds (16 weeks for VLU wounds), or until 100 percent epithelialization, whichever occurs first.
Reported as:
Mean · Weeks
Time to 100 Percent Epithelialization
WeeksVenous Leg Ulcer Participants Assigned to Synthetic Hybrid-Scale Fiber Matrix (Restrata®)Venous Leg Ulcer Participants Assigned to Living Cellular Skin Substitute (Apligraf®)Diabetic Foot Ulcer Participants Assigned to Standard of Care (SOC)Diabetic Foot Ulcer Participants Assigned to Synthetic Hybrid-Scale Fiber Matrix (Restrata)
Time to 100 Percent Epithelialization6 ± 010.8 ± 3.66 ± 09.5 ± 1.0
SecondaryTotal Number of Product Applications

The number of study applications including the initial application until 12 weeks for DFU patients and 16 weeks for VLU patients, or until 100% re-epithelialization, whichever occurs first

Time frame:
Initial application until 12 weeks for DFU patients and 16 weeks for VLU patients, or until 100% re-epithelialization, whichever occurs first
Reported as:
Mean · Number of applications
Total Number of Product Applications
Number of applicationsVenous Leg Ulcer Participants Assigned to Synthetic Hybrid-Scale Fiber Matrix (Restrata®)Venous Leg Ulcer Participants Assigned to Living Cellular Skin Substitute (Apligraf®)Diabetic Foot Ulcer Participants Assigned to Standard of Care (SOC)Diabetic Foot Ulcer Participants Assigned to Synthetic Hybrid-Scale Fiber Matrix (Restrata)
Total Number of Product Applications7.7 ± 2.87.1 ± 2.38.9 ± 4.04.1 ± 1.5

Adverse events

Collected over 2 weeks after healing OR 2 weeks after 12-14 weeks of treatment. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Diabetic Foot Ulcer Participants Assigned to Synthetic Hybrid-Scale Fiber Matrix (Restrata®)0/8 (0%)0/8 (0%)3/8 (37.5%)
Diabetic Foot Ulcer Participants Assigned to Standard of Care0/10 (0%)3/10 (30%)4/10 (40%)
Venous Leg Ulcer Participants Assigned to Synthetic Hybrid-Scale Fiber Matrix (Restrata®)0/14 (0%)1/14 (7.1%)8/14 (57.1%)
Venous Leg Ulcer Participants Assigned to Living Cellular Skin Substitute (Apligraf®)0/16 (0%)0/16 (0%)3/16 (18.8%)
Most frequent serious events
Most frequent serious events
EventDiabetic Foot Ulcer Participants Assigned to Synthetic Hybrid-Scale Fiber Matrix (Restrata®)Diabetic Foot Ulcer Participants Assigned to Standard of CareVenous Leg Ulcer Participants Assigned to Synthetic Hybrid-Scale Fiber Matrix (Restrata®)Venous Leg Ulcer Participants Assigned to Living Cellular Skin Substitute (Apligraf®)
AmputationInfections and infestations0/81/100/140/16
AtherectomyInvestigations0/81/100/140/16
Pain near woundSkin and subcutaneous tissue disorders0/81/100/140/16
FallInjury, poisoning and procedural complications0/80/101/140/16
Most frequent other events
Showing 10 of 21
Most frequent other events
EventDiabetic Foot Ulcer Participants Assigned to Synthetic Hybrid-Scale Fiber Matrix (Restrata®)Diabetic Foot Ulcer Participants Assigned to Standard of CareVenous Leg Ulcer Participants Assigned to Synthetic Hybrid-Scale Fiber Matrix (Restrata®)Venous Leg Ulcer Participants Assigned to Living Cellular Skin Substitute (Apligraf®)
BlisterSkin and subcutaneous tissue disorders1/80/100/140/16
Arteriovenous fistulaVascular disorders1/80/100/140/16
Facial skin infectionSkin and subcutaneous tissue disorders1/80/100/140/16
Skin lesion excisionSkin and subcutaneous tissue disorders1/80/100/140/16
skin ulcerSkin and subcutaneous tissue disorders0/81/101/141/16
HeadacheGeneral disorders0/81/100/140/16
Joint injuryInjury, poisoning and procedural complications0/81/100/140/16
limb injuryInjury, poisoning and procedural complications0/81/100/140/16
Wound infection staphylococcalInfections and infestations0/80/101/141/16
influenza like illnessGeneral disorders0/80/101/140/16

Baseline characteristics

Age, Continuous
Age, Continuous(years)Diabetic Foot Ulcer Participants Assigned to Synthetic Hybrid-Scale Fiber Matrix (Restrata®)Diabetic Foot Ulcer Participants Assigned to Standard of CareVenous Leg Ulcer Participants Assigned to Synthetic Hybrid-Scale Fiber Matrix (Restrata®)Venous Leg Ulcer Participants Assigned to Living Cellular Skin Substitute (Apligraf®)Total
Mean67 ± 12.653 ± 14.559 ± 10.473 ± 12.264 ± 14.7
Sex: Female, Male
Sex: Female, Male(Participants)Diabetic Foot Ulcer Participants Assigned to Synthetic Hybrid-Scale Fiber Matrix (Restrata®)Diabetic Foot Ulcer Participants Assigned to Standard of CareVenous Leg Ulcer Participants Assigned to Synthetic Hybrid-Scale Fiber Matrix (Restrata®)Venous Leg Ulcer Participants Assigned to Living Cellular Skin Substitute (Apligraf®)Total
Female237921
Male677727
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Diabetic Foot Ulcer Participants Assigned to Synthetic Hybrid-Scale Fiber Matrix (Restrata®)Diabetic Foot Ulcer Participants Assigned to Standard of CareVenous Leg Ulcer Participants Assigned to Synthetic Hybrid-Scale Fiber Matrix (Restrata®)Venous Leg Ulcer Participants Assigned to Living Cellular Skin Substitute (Apligraf®)Total
Hispanic or Latino131712
Not Hispanic or Latino7713936
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Diabetic Foot Ulcer Participants Assigned to Synthetic Hybrid-Scale Fiber Matrix (Restrata®)Diabetic Foot Ulcer Participants Assigned to Standard of CareVenous Leg Ulcer Participants Assigned to Synthetic Hybrid-Scale Fiber Matrix (Restrata®)Venous Leg Ulcer Participants Assigned to Living Cellular Skin Substitute (Apligraf®)Total
American Indian or Alaska Native00000
Asian00000
Native Hawaiian or Other Pacific Islander00101
Black or African American03227
White87111440
More than one race00000
Unknown or Not Reported00000
Wound area at baseline in cm^2
Wound area at baseline in cm^2(cm^2)Diabetic Foot Ulcer Participants Assigned to Synthetic Hybrid-Scale Fiber Matrix (Restrata®)Diabetic Foot Ulcer Participants Assigned to Standard of CareVenous Leg Ulcer Participants Assigned to Synthetic Hybrid-Scale Fiber Matrix (Restrata®)Venous Leg Ulcer Participants Assigned to Living Cellular Skin Substitute (Apligraf®)Total
Mean3.0 ± 1.25.0 ± 4.417.7 ± 13.914.4 ± 12.211.6 ± 12.1
08

Study locations

6 sites
  • ILD Research Center
    Vista, California 92083, United States
  • University of Florida - Jacksonville
    Jacksonville, Florida 32209, United States
  • Barry University
    Miami Beach, Florida 33169, United States
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
  • Boston Medical Center
    Boston, Massachusetts 02118, United States
  • Gundersen Health System
    La Crosse, Wisconsin 54601, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2021 to primary completion in Jul 2024, 35 months.

Results were first posted in Feb 2026, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 3, 2021
First posted
Jun 16, 2021
StartActual
Jul 19, 2021
Primary completionActual
Jul 15, 2024
CompletionActual
Aug 1, 2024
Results first posted
Feb 27, 2026
Last update
Feb 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04927702
Responsible party
Sponsor
First posted
Jun 16, 2021
Start date
Jul 19, 2021
Primary completion
Jul 15, 2024
Completion
Aug 1, 2024
Results posted
Feb 27, 2026
Last update
Feb 27, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion